NASDAQ : CBIO

Crescent Biopharma, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 13.39 USD (Oct 30, 2026, 2:56 PM EDT) · Market cap 573.11M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Details

NameCrescent Biopharma, Inc.
SectorHealthcare
IndustryBiotechnology
Employees69
Founded2003
CeoJoshua Brumm
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinKYG2545C1042
CusipG2545C104
Cik0001253689
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Joshua T. BrummChief Executive Officer and Director
Dr. Jonathan McNeill M.D.President and Chief Operating Officer
Dr. Ellie Im M.D.Chief Medical Officer
Richard William Scalzo M.B.A.Chief Financial Officer
Ryan LynchSenior Vice President of Finance, Treasurer and Chief Accounting Officer
Dr. Wenjie Cheng Ph.D.Senior Vice President of Technical Operations
Dr. Jan Pinkas Ph.D.Chief Scientific Officer
Barbara Bispham Hale J.D.General Counsel and Corporate Secretary
Amy ReillyChief Communications Officer
Christopher DoughtyChief Business Officer

Contact

Address300 Fifth Avenue, Waltham, Massachusetts 02451, United States
Phone617 460 5595
Websitehttps://crescentbiopharma.com